Use of PET is widespread and increasing in the United States, mainly for oncologic applications. In November 2006, the National Comprehensive Cancer Network (NCCN) gathered a panel of experts to review the literature and develop clinical recommendations for using PET scans in lymphoma and non–small cell lung, breast, and colorectal cancers. However, because its use is not restricted to these diseases, and evidence is accumulating for its application in other types of cancers, NCCN convened a second meeting in December 2008 to expand on the initial report. A multidisciplinary panel met to discuss the current data on PET application for various tumor types, including genitourinary, gynecologic, pancreatic, hepatobiliary, thyroid, brain, small cell lung, gastric, and esophageal cancers, and sarcoma and myeloma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, the role of PET in oncology, principles of PET use, emerging applications, and possible future developments.
If the inline PDF is not rendering correctly, you can download the PDF file here.
CasneufV, DelrueL, KellesA. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?Acta Gastroenterol Belg2007;70:331–338.
CasneufVDelrueLKellesA. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?Acta Gastroenterol Belg2007;70:331–338.
)| false
DirisamerA, HalpernBS, FloryD. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. Eur J Radiol2009; in press.
DirisamerAHalpernBSFloryD. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. Eur J Radiol2009; in press.
)| false
GerthHU, JuergensKU, DirksenU. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med2007;48:1932–1939.
GerthHUJuergensKUDirksenU. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med2007;48:1932–1939.
)| false
KitajimaK, MurakamiK, YamasakiE. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging2009; in press.
KitajimaKMurakamiKYamasakiE. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging2009; in press.
)| false
LardinoisD, WederW, HanyTF. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med2003;348:2500–2507.
LardinoisDWederWHanyTF. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med2003;348:2500–2507.
)| false
TateishiU, YamaguchiU, SekiK. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology2007;245:839–847.
TateishiUYamaguchiUSekiK. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology2007;245:839–847.
)| false
AntochG, SaoudiN, KuehlH. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol2004;22:4357–4368.
AntochGSaoudiNKuehlH. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol2004;22:4357–4368.
)| false
KelloffGJ, HoffmanJM, JohnsonB. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res2005;11:2785–2808.
KelloffGJHoffmanJMJohnsonB. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res2005;11:2785–2808.
)| false
EaryJF, O’SullivanF, PowitanY. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging2002;29:1149–1154.
EaryJFO’SullivanFPowitanY. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging2002;29:1149–1154.
)| false
OshidaM, UnoK, SuzukiM. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer1998;82:2227–2234.
OshidaMUnoKSuzukiM. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer1998;82:2227–2234.
)| false
CMS final decision memo: Available at: https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=218&. Accessed April 7, 2009.
CMS final decision memo: Available at: https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=218&. Accessed April 7, 2009.
)| false
HillnerBE, SiegelBA, LiuD. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol2008;26:2155–2161.
HillnerBESiegelBALiuD. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol2008;26:2155–2161.
)| false
HillnerBE, SiegelBA, ShieldsAF. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med2008;49:1928–1935.
HillnerBESiegelBAShieldsAF. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med2008;49:1928–1935.
)| false
ChattertonBE, Ho ShonI, BaldeyA. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging2009;36:354–361.
ChattertonBEHo ShonIBaldeyA. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging2009;36:354–361.
)| false
ScottAM, GunawardanaDH, BartholomeuszD. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med2008;49:1593–1600.
ScottAMGunawardanaDHBartholomeuszD. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med2008;49:1593–1600.
)| false
ScottAM, GunawardanaDH, KelleyB. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med2008;49:1451–1457.
ScottAMGunawardanaDHKelleyB. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med2008;49:1451–1457.
)| false
ScottAM, GunawardanaDH, WongJ. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging2009;36:347–353.
ScottAMGunawardanaDHWongJ. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging2009;36:347–353.
)| false
van TinterenH, HoekstraOS, SmitEF. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet2002;359:1388–1393.
van TinterenHHoekstraOSSmitEF. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet2002;359:1388–1393.
)| false
SobhaniI, TiretE, LebtahiR. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer2008;98:875–880.
SobhaniITiretELebtahiR. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer2008;98:875–880.
)| false
van HeijlM, OmlooJM, van Berge HenegouwenMI. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys2008;8:3.
van HeijlMOmlooJMvan Berge HenegouwenMI. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys2008;8:3.
)| false
ShankarLK, HoffmanJM, BacharachS. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med2006;47:1059–1066.
ShankarLKHoffmanJMBacharachS. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med2006;47:1059–1066.
)| false
De WitteO, LevivierM, ViolonP. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery1996;39:470–476; discussion 476–477.
De WitteOLevivierMViolonP. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery1996;39:470–476; discussion 476–477.
)| false
ChaoST, SuhJH, RajaS. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer2001;96:191–197.
ChaoSTSuhJHRajaS. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer2001;96:191–197.
)| false
HustinxR, PourdehnadM, KaschtenB, AlaviA. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am2005;43:35–47.
HustinxRPourdehnadMKaschtenBAlaviA. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am2005;43:35–47.
)| false
SpenceAM, MuziM, MankoffDA. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med2004;45:1653–1659.
SpenceAMMuziMMankoffDA. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med2004;45:1653–1659.
)| false
TsuyuguchiN, SunadaI, IwaiY. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?J Neurosurg2003;98:1056–1064.
TsuyuguchiNSunadaIIwaiY. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?J Neurosurg2003;98:1056–1064.
)| false
GrosuAL, WeberWA, FranzM. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys2005;63:511–519.
GrosuALWeberWAFranzM. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys2005;63:511–519.
)| false
TralinsKS, DouglasJG, StelzerKJ. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med2002;43:1667–1673.
TralinsKSDouglasJGStelzerKJ. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med2002;43:1667–1673.
)| false
AttanasiF, BelcariN, CamardaM. Experimental validation of the filtering approach for dose monitoring in proton therapy at low energy. Phys Med2008;24:102–106.
AttanasiFBelcariNCamardaM. Experimental validation of the filtering approach for dose monitoring in proton therapy at low energy. Phys Med2008;24:102–106.
)| false
KnopfA, ParodiK, PaganettiH. Quantitative assessment of the physical potential of proton beam range verification with PET/CT. Phys Med Biol2008;53:4137–4151.
KnopfAParodiKPaganettiH. Quantitative assessment of the physical potential of proton beam range verification with PET/CT. Phys Med Biol2008;53:4137–4151.
)| false
ParodiK, FerrariA, SommererF, PaganettiH. Clinical CT-based calculations of dose and positron emitter distributions in proton therapy using the FLUKA Monte Carlo code. Phys Med Biol2007;52:3369–3387.
ParodiKFerrariASommererFPaganettiH. Clinical CT-based calculations of dose and positron emitter distributions in proton therapy using the FLUKA Monte Carlo code. Phys Med Biol2007;52:3369–3387.
)| false
ChenJ, CheongJH, YunMJ. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer2005;103:2383–2390.
ChenJCheongJHYunMJ. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer2005;103:2383–2390.
)| false
ShahMA, YeungH, TrocolaR. The characteristics and utility of FDG-PET/CT scans in patients with localized gastric cancer (GC) [abstract]. Presented at the 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 2.
ShahMAYeungHTrocolaR. The characteristics and utility of FDG-PET/CT scans in patients with localized gastric cancer (GC) [abstract]. Presented at the 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 2.
)| false
FlamenP, LerutA, Van CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:3202–3210.
FlamenPLerutAVan CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:3202–3210.
)| false
van WestreenenHL, WesterterpM, BossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:3805–3812.
van WestreenenHLWesterterpMBossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:3805–3812.
)| false
van WestreenenHL, WesterterpM, SloofGW. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg2007;94:1515–1520.
van WestreenenHLWesterterpMSloofGW. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg2007;94:1515–1520.
)| false
WesterterpM, van WestreenenHL, ReitsmaJB. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology2005;236:841–851.
WesterterpMvan WestreenenHLReitsmaJB. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology2005;236:841–851.
)| false
DowneyRJ, AkhurstT, IlsonD. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol2003;21:428–432.
DowneyRJAkhurstTIlsonD. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol2003;21:428–432.
)| false
FlamenP, Van CutsemE, LerutA. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol2002;13:361–368.
FlamenPVan CutsemELerutA. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol2002;13:361–368.
)| false
OttK, FinkU, BeckerK. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol2003;21:460–4610.
OttKFinkUBeckerK. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol2003;21:460–4610.
)| false
WeberWA, OttK, BeckerK. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol2001;19:3058–3065.
WeberWAOttKBeckerK. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol2001;19:3058–3065.
)| false
LordickF, OttK, KrauseBJ. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol2007;8:797–805.
LordickFOttKKrauseBJ. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol2007;8:797–805.
)| false
Clinicaltrials.gov.A phase II trial of preoperative irinotecan, cisplatin and radiation in esophageal cancer. Available at: http://clinicaltrials.gov/ct/show/NCT00316862. Accessed February 9, 2009.
Clinicaltrials.gov.A phase II trial of preoperative irinotecan, cisplatin and radiation in esophageal cancer. Available at: http://clinicaltrials.gov/ct/show/NCT00316862. Accessed February 9, 2009.
)| false
EffertPJ, BaresR, HandtS. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol1996;155:994–998.
EffertPJBaresRHandtS. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol1996;155:994–998.
)| false
HoferC, LaubenbacherC, BlockT. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol1999;36:31–35.
HoferCLaubenbacherCBlockT. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol1999;36:31–35.
)| false
KangDE, WhiteRLJr, ZugerJH. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol2004;171:1806–1809.
KangDEWhiteRLJrZugerJH. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol2004;171:1806–1809.
)| false
FrickeE, MachtensS, HofmannM. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging2003;30:607–611.
FrickeEMachtensSHofmannM. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging2003;30:607–611.
)| false
KaoCH, HsiehJF, TsaiSC. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res2000;20:2189–2192.
KaoCHHsiehJFTsaiSC. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res2000;20:2189–2192.
)| false
PicchioM, TreiberU, BeerAJ. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med2006;47:938–944.
PicchioMTreiberUBeerAJ. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med2006;47:938–944.
)| false
LiuIJ, LaiYH, EspirituJI. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int2006;77:69–75.
LiuIJLaiYHEspirituJI. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int2006;77:69–75.
)| false
WuHC, YenRF, ShenYY. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—a preliminary report. J Cancer Res Clin Oncol2002;128:503–506.
WuHCYenRFShenYY. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—a preliminary report. J Cancer Res Clin Oncol2002;128:503–506.
)| false
XueF, LinLL, DehdashtiF. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol2006;101:147–151.
XueFLinLLDehdashtiF. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol2006;101:147–151.
)| false
SuzukiR, MiyagiE, TakahashiN. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer2007;17:890–896.
SuzukiRMiyagiETakahashiN. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer2007;17:890–896.
)| false
SchwarzJK, SiegelBA, DehdashtiF, GrigsbyPW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA2007;298:2289–2295.
SchwarzJKSiegelBADehdashtiFGrigsbyPW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA2007;298:2289–2295.
)| false
GoldMA. PET in cervical cancer—implications for ‘staging,’ treatment planning, assessment of prognosis, and prediction of response. J Natl Compr Canc Netw2008;6:37–45.
GoldMA. PET in cervical cancer—implications for ‘staging,’ treatment planning, assessment of prognosis, and prediction of response. J Natl Compr Canc Netw2008;6:37–45.
)| false
HusainA, AkhurstT, LarsonS. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol2007;106:177–180.
HusainAAkhurstTLarsonS. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol2007;106:177–180.
)| false
MurakamiM, MiyamotoT, IidaT. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer2006;16(Suppl 1):99–107.
MurakamiMMiyamotoTIidaT. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer2006;16(Suppl 1):99–107.
)| false
ThrallMM, DeLoiaJA, GallionH, AvrilN. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol2007;105:17–22.
ThrallMMDeLoiaJAGallionHAvrilN. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol2007;105:17–22.
)| false
MangiliG, PicchioM, SironiS. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging2007;34:658–666.
MangiliGPicchioMSironiS. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging2007;34:658–666.
)| false
Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). Technology assessment report prepared by UAEPC for AHRQ. Available at: http://www.cms.hhs.gov/determinationprocess/downloads/id54TA.pdf. Accessed February 24, 2009.
Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). Technology assessment report prepared by UAEPC for AHRQ. Available at: http://www.cms.hhs.gov/determinationprocess/downloads/id54TA.pdf. Accessed February 24, 2009.
)| false
SchirrmeisterH, BommerM, BuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361–366.
SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361–366.
)| false
SchirrmeisterH, BuckAK, BergmannL. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm2003;18:841–845.
SchirrmeisterHBuckAKBergmannL. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm2003;18:841–845.
)| false
MileshkinL, BlumR, SeymourJF. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol2004;72:32–37.
MileshkinLBlumRSeymourJF. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol2004;72:32–37.
)| false
NanniC, ZamagniE, FarsadM. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging2006;33:525–531.
NanniCZamagniEFarsadM. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging2006;33:525–531.
)| false
Breyer RJIII, MulliganME, SmithSE. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol2006;35:632–640.
Breyer RJIIIMulliganMESmithSE. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol2006;35:632–640.
)| false
BangS, ChungHW, ParkSW. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol2006;40:923–929.
BangSChungHWParkSW. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol2006;40:923–929.
)| false
ZimnyM, BaresR, FassJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med1997;24:678–682.
ZimnyMBaresRFassJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med1997;24:678–682.
)| false
ChangKJ, NguyenP, EricksonRA. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc1997;45:387–393.
ChangKJNguyenPEricksonRA. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc1997;45:387–393.
)| false
MertzHR, SechopoulosP, DelbekeD, LeachSD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc2000;52:367–371.
MertzHRSechopoulosPDelbekeDLeachSD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc2000;52:367–371.
)| false
HeinrichS, GoerresGW, SchaferM. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg2005;242:235–243.
HeinrichSGoerresGWSchaferM. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg2005;242:235–243.
)| false
KimJY, KimMH, LeeTY. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol2008;103:1145–1151.
KimJYKimMHLeeTY. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol2008;103:1145–1151.
)| false
PetrowskyH, WildbrettP, HusarikDB. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol2006;45:43–50.
PetrowskyHWildbrettPHusarikDB. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol2006;45:43–50.
)| false
Rodriguez-FernandezA, Gomez-RioM, Llamas-ElviraJM. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg2004;188:171–175.
Rodriguez-FernandezAGomez-RioMLlamas-ElviraJM. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg2004;188:171–175.
)| false
AndersonCD, RiceMH, PinsonCW. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg2004;8:90–97.
AndersonCDRiceMHPinsonCW. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg2004;8:90–97.
)| false
ParkJW, KimJH, KimSK. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med2008;49:1912–1921.
ParkJWKimJHKimSK. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med2008;49:1912–1921.
)| false
WudelLJJr, DelbekeD, MorrisD. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg2003;69:117–124; discussion 124–116.
WudelLJJrDelbekeDMorrisD. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg2003;69:117–124; discussion 124–116.
)| false
YangSH, SuhKS, LeeHW. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl2006;12:1655–1660.
YangSHSuhKSLeeHW. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl2006;12:1655–1660.
)| false
ChikamotoA, TsujiT, TakamoriH. The diagnostic efficacy of FDG-PET in the local recurrence of hilar bile duct cancer. J Hepatobiliary Pancreat Surg2006;13:403–408.
ChikamotoATsujiTTakamoriH. The diagnostic efficacy of FDG-PET in the local recurrence of hilar bile duct cancer. J Hepatobiliary Pancreat Surg2006;13:403–408.
)| false
AndersonGS, BrinkmannF, SoulenMC. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med2003;28:192–197.
AndersonGSBrinkmannFSoulenMC. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med2003;28:192–197.
)| false
PaudyalB, OriuchiN, PaudyalP. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep2007;18:1469–1473.
PaudyalBOriuchiNPaudyalP. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep2007;18:1469–1473.
)| false
ZhaoM, WuPH, ZengYX. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Ai Zheng2005;24:1118–1123[in Chinese].
ZhaoMWuPHZengYX. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Ai Zheng2005;24:1118–1123[in Chinese].
)| false
FranziusC, Daldrup-LinkHE, SciukJ. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol2001;12:479–486.
FranziusCDaldrup-LinkHESciukJ. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol2001;12:479–486.
)| false
LucasJD, O’DohertyMJ, WongJC. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br1998;80:441–447.
LucasJDO’DohertyMJWongJC. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br1998;80:441–447.
)| false
FranziusC, SciukJ, Daldrup-LinkHE. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med2000;27:1305–1311.
FranziusCSciukJDaldrup-LinkHE. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med2000;27:1305–1311.
)| false
DemetriGD, von MehrenM, BlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472–480.
DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472–480.
)| false
DemetriGD, van OosteromAT, GarrettCR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:1329–1338.
DemetriGDvan OosteromATGarrettCR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:1329–1338.
)| false
AntochG, KanjaJ, BauerS. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med2004;45:357–365.
AntochGKanjaJBauerS. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med2004;45:357–365.
)| false
van den AbbeeleA, MelenevskyY, de VriesD. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 9006.
van den AbbeeleAMelenevskyYde VriesD. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 9006.
)| false
PriorJO, MontemurroM, OrcurtoMV. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol2009;27:439–445.
PriorJOMontemurroMOrcurtoMV. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol2009;27:439–445.
)| false
ChinRJr, McCainTW, MillerAA. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer2002;37:1–6.
ChinRJrMcCainTWMillerAA. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer2002;37:1–6.
)| false
HauberHP, BohuslavizkiKH, LundCH. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest2001;119:950–954.
HauberHPBohuslavizkiKHLundCH. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest2001;119:950–954.
)| false
KutV, SpiesW, SpiesS. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol2007;30:45–50.
KutVSpiesWSpiesS. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol2007;30:45–50.
)| false
VinjamuriM, CraigM, Campbell-FontaineA. Can positron emission tomography be used as a staging tool for small-cell lung cancer?Clin Lung Cancer2008;9:30–34.
VinjamuriMCraigMCampbell-FontaineA. Can positron emission tomography be used as a staging tool for small-cell lung cancer?Clin Lung Cancer2008;9:30–34.
)| false
LeeHY, ChungJK, JeongJM. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Ann Nucl Med2008;22:281–286.
LeeHYChungJKJeongJM. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Ann Nucl Med2008;22:281–286.
)| false
Albores-SaavedraJ, HensonDE, GlazerE, SchwartzAM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol2007;18:1–7.
Albores-SaavedraJHensonDEGlazerESchwartzAM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol2007;18:1–7.
)| false
PrymaDA, SchoderH, GonenM. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med2006;47:1260–1266.
PrymaDASchoderHGonenM. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med2006;47:1260–1266.
)| false
GoughJ, Scott-CoombesD, Fausto PalazzoF. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg2008;32:1264–1268.
GoughJScott-CoombesDFausto PalazzoF. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg2008;32:1264–1268.
)| false
OngSC, SchoderH, PatelSG. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med2007;48:501–507.
OngSCSchoderHPatelSG. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med2007;48:501–507.
)| false
LeboulleuxS, SchroederPR, SchlumbergerM, LadensonPW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab2007;3:112–121.
LeboulleuxSSchroederPRSchlumbergerMLadensonPW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab2007;3:112–121.
)| false
LeboulleuxS, SchroederPR, BusaidyNL. Assessment of the incremental value of recombinant TSH stimulation before FDG PET/CT imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab2009;94:1310–1316.
LeboulleuxSSchroederPRBusaidyNL. Assessment of the incremental value of recombinant TSH stimulation before FDG PET/CT imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab2009;94:1310–1316.
)| false
SchluterB, BohuslavizkiKH, BeyerW. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med2001;42:71–76.
SchluterBBohuslavizkiKHBeyerW. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med2001;42:71–76.
)| false
JuweidME, StroobantsS, HoekstraOS. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol2007;25:571–578.
JuweidMEStroobantsSHoekstraOS. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol2007;25:571–578.
)| false
HillnerBE, SiegelBA, ShieldsAF. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer2009;115:410–418.
HillnerBESiegelBAShieldsAF. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer2009;115:410–418.
)| false
PirotteB, GoldmanS, MassagerN. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg2004;101:476–483.
PirotteBGoldmanSMassagerN. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg2004;101:476–483.
)| false
RischinD, HicksRJ, FisherR. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol2006;24:2098–2104.
RischinDHicksRJFisherR. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol2006;24:2098–2104.
)| false
